{"id":64242,"date":"2026-04-29T21:40:08","date_gmt":"2026-04-29T13:40:08","guid":{"rendered":"https:\/\/flcube.com\/?p=64242"},"modified":"2026-04-29T21:40:09","modified_gmt":"2026-04-29T13:40:09","slug":"abbott-secures-fda-clearance-and-ce-mark-for-ultreon-3-0-ai-powered-oct-imaging-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64242","title":{"rendered":"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform"},"content":{"rendered":"\n<p><strong>Abbott<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABT:NYSE\">NYSE: ABT<\/a>) announced it has received <strong>U.S. Food and Drug Administration (FDA) clearance<\/strong> and <strong>CE Mark approval<\/strong> for its <strong>next-generation Ultreon 3.0 Software<\/strong>, an <strong>artificial intelligence (AI)-powered imaging platform<\/strong> that enhances <strong>percutaneous coronary intervention (PCI)<\/strong> procedures through real-time optical coherence tomography (OCT) guidance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approvals-summary\">Regulatory Approvals Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authorities<\/strong><\/td><td>U.S. FDA (clearance) and European Commission (CE Mark)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ultreon 3.0 Software<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>AI-powered optical coherence tomography (OCT) imaging<\/td><\/tr><tr><td><strong>Clinical Application<\/strong><\/td><td>Percutaneous coronary intervention (PCI) for blocked heart arteries<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>April 28, 2026<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Immediate commercial availability in U.S. and EU markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-clinical-innovation\">Technology Profile &amp; Clinical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Imaging Modality:<\/strong> <strong>Optical coherence tomography (OCT)<\/strong> providing high-resolution visualization of coronary artery blockages<\/li>\n\n\n\n<li><strong>AI Integration:<\/strong> Real-time artificial intelligence analysis of plaque composition and morphology<\/li>\n\n\n\n<li><strong>Clinical Decision Support:<\/strong> Automated assessment of plaque type to guide optimal stent selection<\/li>\n\n\n\n<li><strong>Workflow Enhancement:<\/strong> Fully integrated platform supporting faster, more precise PCI procedures<\/li>\n\n\n\n<li><strong>Real-Time Guidance:<\/strong> Immediate feedback during minimally invasive procedures for improved outcomes<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-benefits-amp-physician-workflow\">Clinical Benefits &amp; Physician Workflow<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-enhanced-visualization\">Enhanced Visualization<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Detailed structural imaging of coronary blockages with micron-level resolution<\/li>\n\n\n\n<li>Clear differentiation between calcified, fibrotic, and lipid-rich plaque types<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ai-powered-decision-making\">AI-Powered Decision Making<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Automated plaque characterization to inform treatment strategy<\/li>\n\n\n\n<li>Optimal stent sizing and placement recommendations based on vessel anatomy<\/li>\n\n\n\n<li>Reduced procedural variability through standardized decision support<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-procedural-efficiency\">Procedural Efficiency<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Streamlined workflow integration minimizing setup time<\/li>\n\n\n\n<li>Real-time guidance reducing need for repeat imaging or adjustments<\/li>\n\n\n\n<li>Potential to shorten procedure duration while improving precision<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-implications\">Strategic Market Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Segment<\/th><th>Strategic Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Interventional Cardiology<\/strong><\/td><td>Strengthens Abbott&#8217;s leadership in coronary imaging and guidance<\/td><\/tr><tr><td><strong>AI Medical Devices<\/strong><\/td><td>Demonstrates successful integration of artificial intelligence into clinical workflows<\/td><\/tr><tr><td><strong>Global Commercialization<\/strong><\/td><td>Dual regulatory approval enables immediate revenue generation in key markets<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Differentiates from traditional angiography-only approaches and non-AI imaging platforms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-portfolio-integration\">Portfolio Integration<\/h2>\n\n\n\n<p>The Ultreon 3.0 platform represents a significant enhancement to Abbott&#8217;s comprehensive cardiovascular portfolio, complementing its existing stent systems, diagnostic catheters, and imaging technologies. The AI-powered capabilities position Abbott at the forefront of the growing trend toward data-driven, precision interventional cardiology.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, product capabilities, and market opportunities. Actual results may differ due to risks including market adoption rates, competitive responses, and evolving regulatory requirements for AI-enabled medical devices.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[503,870,15],"class_list":["post-64242","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-abbott","tag-nyse-abt","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI)-powered imaging platform that enhances percutaneous coronary intervention (PCI) procedures through real-time optical coherence tomography (OCT) guidance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64242\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform\" \/>\n<meta property=\"og:description\" content=\"Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI)-powered imaging platform that enhances percutaneous coronary intervention (PCI) procedures through real-time optical coherence tomography (OCT) guidance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64242\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T13:40:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T13:40:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64242#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64242\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform\",\"datePublished\":\"2026-04-29T13:40:08+00:00\",\"dateModified\":\"2026-04-29T13:40:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64242\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbott\",\"NYSE: ABT\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64242#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64242\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64242\",\"name\":\"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-29T13:40:08+00:00\",\"dateModified\":\"2026-04-29T13:40:09+00:00\",\"description\":\"Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI)-powered imaging platform that enhances percutaneous coronary intervention (PCI) procedures through real-time optical coherence tomography (OCT) guidance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64242#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64242\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64242#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI)-powered imaging platform that enhances percutaneous coronary intervention (PCI) procedures through real-time optical coherence tomography (OCT) guidance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64242","og_locale":"en_US","og_type":"article","og_title":"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform","og_description":"Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI)-powered imaging platform that enhances percutaneous coronary intervention (PCI) procedures through real-time optical coherence tomography (OCT) guidance.","og_url":"https:\/\/flcube.com\/?p=64242","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-29T13:40:08+00:00","article_modified_time":"2026-04-29T13:40:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64242#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64242"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform","datePublished":"2026-04-29T13:40:08+00:00","dateModified":"2026-04-29T13:40:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64242"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbott","NYSE: ABT","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64242#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64242","url":"https:\/\/flcube.com\/?p=64242","name":"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-29T13:40:08+00:00","dateModified":"2026-04-29T13:40:09+00:00","description":"Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI)-powered imaging platform that enhances percutaneous coronary intervention (PCI) procedures through real-time optical coherence tomography (OCT) guidance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64242#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64242"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64242#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64242"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64242\/revisions"}],"predecessor-version":[{"id":64243,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64242\/revisions\/64243"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}